ArticleDiabetes2025
When Does Metabolic Memory Start? Insights From the Association of Medical Diabetologists Annals Initiative on Stringent HbA1c Targets.
Article in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Bridging the gap in early cardio-renal risk prevention in type 2 diabetes: evidence, guidelines, and real-world insights from the PRECARE NO LiMITS initiative.Acta diabetologica · 2026Review
- Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Causes and consequences of discontinuation of GLP1RAs or tirzepatide.Nature reviews. Endocrinology · 2026Review
- A Modified Delphi consensus on early management of combined cardiovascular risk factors in adult patients with type 2 diabetes in Italy.Acta diabetologica · 2026Article
- Age-specific effects of hemoglobin A1c, blood pressure, and cholesterol levels on incident cardiovascular diseases among adults with diabetes in China: a 10-year prospective cohort study.Life metabolism · 2026Article
- Impact of early and tight HbA1c control on the risk of long-term complications and cardiovascular death in patients with type 2 diabetes from the Swedish National Diabetes Register.Diabetes, obesity & metabolism · 2026Article
- Clinical characteristics and intensification patterns in subjects with "early" type 2 diabetes in Italy- an analysis from the AMD annals initiative.Acta diabetologica · 2026Article
- The legacy effect of early HbA1c control on microvascular complications and hospital admissions in type 2 diabetes: findings from a large UK study.Therapeutic advances in endocrinology and metabolism · 2025Article
- Diabetes: Recent Advances and Future Perspectives.Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Early, intensive glycemic control in patients with type 2 diabetes (T2D) is associated with long-term benefits in cardiovascular disease (CVD) development. Evidence on benefits of achieving HbA1c targets close to normal values is scant. Individuals with newly diagnosed T2D, without CVD at baseline, were identified in an Italian clinical registry (n = 251,339). We adopted three definitions of early exposure periods (0-1, 0-2, and 0-3 years). Mean HbA1c was categorized into HbA1c <5.7%, 5.7-6.4%, 6.5-7.0%, 7.1-8.0%, and >8.0%. The outcome was the incidence of major cardiovascular events. After a mean follow-up of 4.6 ± 2.9 years, at multivariate Cox regression analysis, compared with mean HbA1c <5.7% during the first year after diagnosis, the increase in the risk of CVD was 24%, 42%, 49%, and 56% for patients with HbA1c of 5.7-6.4%, 6.5-7.0%, 7.1-8.0%, and >8.0%, respectively. The same trend was documented in all exposure periods. In conclusion, our data support that an early achievement of stringent targets of HbA1c <5.7% is worthy for CVD prevention. ARTICLE HIGHLIGHTS:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.